Table 3

Relationship between PTEN mutation and clinicopathological features

PTEN mutation in any exonPTEN mutation only outside exons 5–7
No./total (%)PNo./total (%)P
Age
 ≤6027/46 (59)12/46 (26)
 >6010/21 (48)0.46/21 (29)0.8
Menopause
 Pre-7/17 (41)5/17 (29)
 Post-30/50 (60)0.1813/50 (26)0.8
Gravidity
 07/13 (54)4/13 (31)
 ≥130/54 (56)0.914/54 (26)0.7
Parity
 09/16 (56)4/16 (25)
 ≥128/51 (55)0.914/51 (28)>0.999
BMI
 ≤2532/53 (60)15/53 (28)
 >255/14 (36)0.103/14 (21)0.7
Diabetes mellitus
 Absent30/56 (54)14/56 (25)
 Present7/11 (64)0.74/11 (36)0.5
Histological grade
 G117/37 (46)9/37 (24)
 G2–3/nonendometrioid20/30 (67)0.099/30 (30)0.6
Peritoneal cytology
 Negative28/52 (54)14/52 (27)
 Positive9/15 (60)0.74/15 (27)>0.999
Muscular invasion
 <2/323/43 (54)13/43 (30)
 >2/314/24 (58)0.75/24 (21)0.4
Cervical involvement
 Negative27/49 (55)14/49 (29)
 Positive10/18 (59)1.04/18 (22)0.8
Adnexal involvement
 Negative31/55 (56)17/55 (31)
 Positive6/12 (50)0.71/12 (8)0.2
Peritoneal involvement
 Negative31/56 (55)16/56 (29)
 Positive6/11 (55)1.02/11 (18)0.7
Lymph nodes
 Negative24/47 (51)14/47 (30)
 Positive9/15 (60)0.53/15 (20)0.5
FIGO stage
 Stage I/II22/38 (58)12/38 (32)
 Stage III/IV15/29 (52)0.66/29 (21)0.3